Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study - Top-Institutions - MDSpire

Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study

  • By

  • Ronja Hietikko

  • Tuomas Mirtti

  • Tuomas P. Kilpeläinen

  • Teemu Tolonen

  • Anne Räisänen-Sokolowski

  • Stig Nordling

  • Jill Hannus

  • Marita Laurila

  • Kimmo Taari

  • Teuvo L. J. Tammela

  • Reija Autio

  • Kari Natunen

  • Anssi Auvinen

  • Antti Rannikko

  • April 6, 2024

  • 0 min

Share

Top Institutions in Urology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Urologic Oncology
    • Radiology
    • Pathology

  • #2

    National Cancer Institute (NCI), NIH
    National Cancer Institute (NCI), NIH

    Bethesda, MD

    Key Differentiators

    • Oncology
    • Radiology
    • Pathology

  • #3

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Urology
    • Radiology
    • Pathology

  • #4

    Helsinki University Hospital
    Helsinki University Hospital

    Helsinki, Finland

    Key Differentiators

    • Urology
    • Radiology
    • Pathology

  • #5

    Radboud University Medical Center
    Radboud University Medical Center

    Nijmegen, Netherlands

    Key Differentiators

    • Urology
    • Radiology
    • Pathology

Original Source(s)

Expected impact of MRI-targeted biopsy interreader variability among uropathologists on ProScreen prostate cancer screening trial: a pre-trial validation study

  • by Ronja Hietikko, Tuomas Mirtti, Tuomas P. Kilpeläinen, Teemu Tolonen, Anne Räisänen-Sokolowski, Stig Nordling, Jill Hannus, Marita Laurila, Kimmo Taari, Teuvo L. J. Tammela, Reija Autio, Kari Natunen, Anssi Auvinen, Antti Rannikko

  • April 6, 2024

Related Content

Combined T2 and diffusion-weighted MR imaging with template prostate biopsies in men suspected with prostate cancer but negative transrectal ultrasound-guided biopsies

Defining the role of multiparametric MRI in predicting prostate cancer extracapsular extension

Is it suitable to eliminate bone scan for prostate cancer patients with PSA ≤ 20 ng/mL?